168 related articles for article (PubMed ID: 6987030)
1. Comparison of methods of evaluating nephrotoxicity of cis-platinum.
Jones BR; Bhalla RB; Mladek J; Kaleya RN; Gralla RJ; Alcock NW; Schwartz MK; Young CW; Reidenberg MM
Clin Pharmacol Ther; 1980 Apr; 27(4):557-62. PubMed ID: 6987030
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
3. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
5. Studies of enzymuria and beta 2-microglobulinuria in patients receiving prophylactic cefotaxime in obstetric and gynaecological surgery.
Ishikawa M; Yamashita K; Shimizu T
Drugs; 1988; 35 Suppl 2():178-80. PubMed ID: 3293974
[TBL] [Abstract][Full Text] [Related]
6. Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma.
Buamah PK; Howell A; Whitby H; Harpur ES; Gescher A
Cancer Chemother Pharmacol; 1982; 8(3):281-4. PubMed ID: 6127169
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of urinary N-acetyl-beta-D-glucosaminidase (NAG), alanine-aminopeptidase (AAP) and beta-2-microglobulin (beta 2M) in evaluating nephrotoxicity of gentamicin.
Gibey R; Dupond JL; Alber D; Leconte des Floris R; Henry JC
Clin Chim Acta; 1981 Oct; 116(1):25-34. PubMed ID: 6172216
[TBL] [Abstract][Full Text] [Related]
8. Renal injury in patients with rheumatoid arthritis treated with gold.
Merle LJ; Reidenberg MM; Camacho MT; Jones BR; Drayer DE
Clin Pharmacol Ther; 1980 Aug; 28(2):216-22. PubMed ID: 6994990
[TBL] [Abstract][Full Text] [Related]
9. Urinary endothelin-1-like immunoreactivity in young male patients with testicular cancer treated by cis-platinum: comparison with other urinary parameters.
Takeda M; Komeyama T; Tsutsui T; Mizusawa T; Go H; Hatano A; Tanikawa T
Clin Sci (Lond); 1994 Jun; 86(6):703-7. PubMed ID: 7520380
[TBL] [Abstract][Full Text] [Related]
10. Follow-up study of enzymuria and beta 2 microglobulinuria during cis-platinum treatment.
Tirelli AS; Colombo N; Cavanna G; Mangioni C; Assael BM
Eur J Clin Pharmacol; 1985; 29(3):313-8. PubMed ID: 3908127
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of N-acetyl-glucosaminidase and beta-2-microglobulin as early markers of gentamicin nephrotoxicity in neonates.
Gouyon JB; Aujard Y; Abisror A; Laudignon N; d'Athis P; Jacqz E; Biou D; Demelier JF; Mathieu H
Dev Pharmacol Ther; 1987; 10(2):145-52. PubMed ID: 3301233
[TBL] [Abstract][Full Text] [Related]
12. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
13. Renal tubular function in patients treated with high-dose cisplatin.
Daugaard G; Abildgaard U; Holstein-Rathlou NH; Bruunshuus I; Bucher D; Leyssac PP
Clin Pharmacol Ther; 1988 Aug; 44(2):164-72. PubMed ID: 2840230
[TBL] [Abstract][Full Text] [Related]
14. Urinary biomarkers in assessing the nephrotoxic potential of gentamicin in solitary kidney patients after 7 days of therapy.
Gluhovschi G; Gadalean F; Gluhovschi C; Velciov S; Petrica L; Bob F; Bozdog G; Kaycsa A
Ren Fail; 2014 May; 36(4):534-40. PubMed ID: 24456153
[TBL] [Abstract][Full Text] [Related]
15. [Acute nephrotoxicity by CDDP (on tubular damage)].
Higuchi K; Negoro Y; Suzuki M; Noguchi M; Nakanishi M; Ishihara M; Nakano M
Gan To Kagaku Ryoho; 1991 Jan; 18(1):85-9. PubMed ID: 1987905
[TBL] [Abstract][Full Text] [Related]
16. In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat.
Smith MA; Smith JH; Litterst CL; Copley MP; Uozumi J; Boyd MR
Fundam Appl Toxicol; 1988 Jan; 10(1):62-72. PubMed ID: 3350230
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.
Pendyala L; Madajewicz S; Lele SB; Arbuck SG; Creaven PJ
Cancer Chemother Pharmacol; 1985; 15(3):203-7. PubMed ID: 4053265
[TBL] [Abstract][Full Text] [Related]
18. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
19. Asymptomatic primary hyper- N-acetyl-beta-D-glucosaminidaseuria: a new clinical entity?
Asami T; Soichiro O; Kasahara T; Uchiyama M
Pediatr Nephrol; 2002 Jul; 17(7):560-5. PubMed ID: 12172776
[TBL] [Abstract][Full Text] [Related]
20. Assessment of urinary retinol-binding protein as an index of proximal tubular injury.
Bernard AM; Vyskocil AA; Mahieu P; Lauwerys RR
Clin Chem; 1987 Jun; 33(6):775-9. PubMed ID: 3297418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
